Covid-19 Vaccine Effectiveness in New York State
뉴욕주의 Covid-19 백신 효과
Comparative Study
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
Ad26
Ad26.COV2.S
Ad26.COV2.S vaccine
Admission
age
B.1.617.2
BNT162b2
cause
circulating variants
Cohort
cohorts
coronavirus
coronavirus disease
Coronavirus disease 2019
Decline
declined
declines
defined
delta variant
diagnosed
drug
Drug administration
Effectiveness
food
Food and Drug Administration
greater
hospital
Hospitalization
laboratory-confirmed
Laboratory-confirmed COVID-19
median
mRNA
mRNA-1273
nadir
New York
Older
predominant
Prevalence
recipient
remained
SARS-CoV-2
severe acute respiratory syndrome Coronavirus
state
the median
the United State
United States
used data
vaccination
Vaccine
Vaccines
variant
waning immunity
[DOI] 10.1056/NEJMoa2116063 PMC 바로가기 [Article Type] Comparative Study
[DOI] 10.1056/NEJMoa2116063 PMC 바로가기 [Article Type] Comparative Study